Court restrains defendants from unauthorized use of Finecure's copyrighted website content and product artwork, affirming prima facie case of copyright violation
In a significant decision dated November 5, 2026, the Delhi High Court, presided over by Mr. Justice Tejas Karia, granted an interim injunction in favor of Finecure Pharmaceuticals Limited, a leading pharmaceutical and nutraceutical manufacturer, in a copyright infringement suit against Cubit Lifesciences LLP and associated defendants.
The plaintiff, Finecure Pharmaceuticals, has been in the pharmaceutical business since 1996 and boasts a broad portfolio of over 250 formulations marketed internationally under various brand names such as FINEMOX, FINETRIAX, and MENUVIT. Finecure is the registered copyright owner of the original artistic and literary works embodied in its corporate website www.finecurepharma.com, including product descriptions, photographs, graphics, and the overall design and layout.
The suit arose after Finecure discovered that the defendants had launched a website www.cubitlifesciences.com, which substantially reproduced and adapted Finecure's copyrighted content without authorization. The impugned website mirrored Finecure's corporate identity, including details like company identification numbers, address, tagline "Making Lives Healthier," product packaging artwork, photographs, and even business credentials and achievements. This unauthorized use was deemed to amount to infringement under Sections 14 and 51 of the Copyright Act, 1957.
The Court, after examining the evidence including Finecure's copyright registration and an assignment letter from the original website developer, observed that the plaintiff had established a strong prima facie case of copyright infringement. The defendants failed to demonstrate any legal right or authorization to use the copyrighted material. The Court noted that allowing continued unauthorized use would cause irreparable harm to the plaintiff's brand reputation and commercial interests, which monetary compensation would not adequately address.
Accordingly, the Court restrained the defendants, their partners, officers, and agents from uploading, reproducing, publishing, or otherwise infringing upon the plaintiff's copyrighted works in any manner. The Court also allowed the plaintiff to amend pleadings and add further claims and parties, reflecting the evolving nature of the litigation.
The judgment also granted the plaintiff exemption from pre-institution mediation due to the urgency of the relief sought, following Supreme Court precedent. The plaintiff was given two weeks to deposit court fees and permitted to file additional documents to support its case.
This ruling underscores the judiciary's commitment to protecting intellectual property rights in the pharmaceutical sector, especially in cases involving digital content and website material, which are critical to a company's brand identity and business operations.
Bottom Line:
Copyright infringement - Prima facie case established for copyright infringement involving reproduction, adaptation, and communication of the plaintiff's copyrighted works without authorisation - Defendants restrained from further infringing on the plaintiff's copyrighted works.
Statutory provision(s):
Copyright Act, 1957 Sections 14, 51; Civil Procedure Code, 1908 Order 39 Rules 1 & 2, Sections 149, 151; Commercial Courts Act, 2015 Section 12A; Civil Procedure Code, 1908 Order 2 Rule 2; Order 11 Rule 1(4)
Finecure Pharmaceuticals Limited v. Nilesh Jain, (Delhi) : Law Finder Doc Id # 3033576